The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGFβRII (such as an anti-PD-L1:TGFβ-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments.

The present invention relates to a capsule comprising a faecal composition for oral administration wherein the faecal composition comprises a stool fraction and a diluent, wherein the stool fraction comprises one or more non-pathogenic microorganisms, and wherein the diluent comprises a cryoprotectant resulting in a final concentration of cryoprotectant in the faecal composition below 8% (v/v) cryoprotectant.

The present invention relates to a capsule comprising a faecal composition for oral administration wherein the faecal composition comprises a stool fraction and a diluent, wherein the stool fraction comprises one or more non-pathogenic microorganisms, and wherein the diluent comprises a cryoprotectant resulting in a final concentration of cryoprotectant in the faecal composition below 8% (v/v) cryoprotectant.

The present invention relates generally to the field of protease-responsive drug delivery hydrogels, uses thereof, and related methods of their production. More particularly, the invention relates to hydrogels which release anti-inflammatory agents upon reaction with inflammation-related proteases.

An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (C1-INH), exhibiting a higher stability for prolonged storage and a reduced formation of aggregates of said esterase inhibitor (C1-INH) upon storage for ameliorated use in treating or preventing disorders related to kinin formation.

The present invention relates to pharmaceutical formulations comprising the C1 esterase inhibitor (C1-INH), exhibiting a higher stability for prolonged storage and a reduced formation of aggregates of said esterase inhibitor (C1-INH) upon storage for ameliorated use in treating or preventing disorders related to kinin formation.

The present invention relates to a hydrogel formulation for delivering probiotics including a hydrogel, probiotics and zwitterionic buffer as an active ingredient, a composition for delivering probiotics comprising the same and a method of preparing the same, which adjust and maintain the internal pH of the hydrogel even in the gastric juice environment, thereby increasing the survival rate of the probiotics in the gastric juice and improving the delivery rate to the large intestine, by further adding zwitterionic buffer capable of maintaining pH to the hydrogel encapsulated with probiotics.

The present invention relates to a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (a dual-linker) containing a 2,3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.